Cargando…
Efficacy and safety of a novel naltrexone treatment for dry eye in type 1 diabetes
BACKGROUND: Dry eye disease (DED) is a prevalent complication of diabetes and presents as reduced tear production and/or increased corneal surface sensitivity often with secondary ocular surface changes. This study examined the safety and efficacy of a proprietary new eye drop formulation for topica...
Autores principales: | McLaughlin, Patricia J., Sassani, Joseph W., Titunick, Michelle B., Zagon, Ian S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6348650/ https://www.ncbi.nlm.nih.gov/pubmed/30691415 http://dx.doi.org/10.1186/s12886-019-1044-y |
Ejemplares similares
-
Naltrexone as a Novel Therapeutic for Diabetic Corneal Complications
por: McLaughlin, Patricia J., et al.
Publicado: (2020) -
Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats
por: McLaughlin, Patricia J., et al.
Publicado: (2023) -
Sex Differences in Diabetic Ocular Surface Complications and Dysregulation of the OGF-OGFr Pathway
por: Zagon, Ian S., et al.
Publicado: (2022) -
Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis
por: Ludwig, Michael D, et al.
Publicado: (2016) -
The Yin and Yang of the Opioid Growth Regulatory System: Focus on Diabetes—The Lorenz E. Zimmerman Tribute Lecture
por: Sassani, Joseph W., et al.
Publicado: (2016)